GSK throws €142m behind innovative vaccine developer CureVac

Nicola Sturgeon visit to GlaxoSmithKline

British drug giant GlaxoSmithKline has backed a “cutting edge” player in the race to develop a vaccine for coronavirus.

GSK said it was putting £130m (€142m) into CureVac for 10% of the business and would make an upfront payment of £104m (€114m).